<DOC>
	<DOCNO>NCT01650090</DOCNO>
	<brief_summary>To establish whether treatment Inhaled Lipid Cisplatin ( ILC ) effective delaying/preventing pulmonary relapse osteosarcoma patient complete surgical remission follow one two prior pulmonary relapse .</brief_summary>
	<brief_title>Phase 2 Study Inhaled Lipid Cisplatin Pulmonary Recurrent Osteosarcoma</brief_title>
	<detailed_description>ILC novel formulation cisplatin , design inhalation nebulization . The anticipated pulmonary benefit ILC systemic cisplatin therapy threefold : - Increased local cisplatin concentration - Sustained release cisplatin lung - Minimal systemic exposure cisplatin In study , patient currently surgical complete remission ( CR ) follow one two prior relapse osteosarcoma involve pulmonary disease treat ILC every two week one year . ILC administer via nebulization .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . History osteosarcoma metastatic lung ( ) . ( First second pulmonary recurrence ( ) remove surgery , previous secondline systemic chemotherapy allow ) . 2 . Patients must macroscopically disease free follow pulmonary metastectomy single multiple lesion . Complete remission surgically ( free macroscopic disease ) require . Pleural disruption and/or microscopic positive margin allow . 3 . Age ≥13 year . 4 . Patients must recover sufficiently acute adverse effect prior therapy , exclude alopecia . 5 . Patients must ECOG performance status 02 . ( Lansky score 50100 &lt; 16 year old ) . 6 . Patients must recover sufficiently surgery adequate airflow pulmonary reserve . This decision investigator 's discretion take consideration presurgery pulmonary function . ( As guideline : adequate airflow define measure Forced Expiratory Volume ( FEV1 ) less 50 % predict value adequate pulmonary reserve evidence FEV1/FVC ratio 65 % great ) . 7 . Patients must adequate renal function define serum creatinine ≤ 1.5 mg/dl . 8 . Patients must adequate liver function define total bilirubin ≤ 1.5 mg/dl ALT AST &lt; 2.5 time institution 's upper normal limit . 9 . Patients must adequate bone marrow function define absolute neutrophil count ( ANC ) ≥ 1,000/mm3 platelet count ≥ 100,000/mm3 . 10 . Signed informed consent include , applicable , consent patient 's legal guardian . 1 . Current extrapulmonary disease . 2 . Current macroscopic pulmonary lesion . 3 . Greater 2 pulmonary recurrence . 4 . Greater 4 week since thoracotomy render patient free macroscopic disease . 5 . Females pregnant breastfeeding . 6 . Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk patient study . 7 . Contraindication unwillingness undergo multiple CT scan chest Xrays . 8 . Unwillingness inability comply study protocol reason . 9 . Participation investigational drug device study treatment antineoplastic agent within 14 day first day dose study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pulmonary relapse</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Lung metastasis</keyword>
	<keyword>Pediatric osteosarcoma</keyword>
	<keyword>Inhaled chemotherapy</keyword>
	<keyword>Inhaled Lipid Cisplatin</keyword>
</DOC>